

Supplementary Table 1: Key clinical characteristics of LADA subset at baseline and at 1 and 5 years after bariatric surgery.

Pre-operative findings								1 year post-op		5 years post-op	
Gender; Age (years)	Diabetes diagnosis (years)	HbA1c and diabetes therapy	Weight in kg and (BMI in kg/m <sup>2</sup> )	Features of metabolic syndrome or autoimmunity	GAD (IU/mL)	IA2 (IU/mL)	Plasma C-peptide (pmol/L)	Weight in kg (% weight change)	HbA1c and diabetes therapy	Weight in kg (% weight change)	HbA1c and diabetes therapy
F; 47*	0.6	61; MF	109 (42.6)	Dyslipidaemia	72	<15	944	88 (-19)	39; nil	109 (0)	49; MF
F; 44* (deceased 2018)	9	55; MF, pioglitazone and insulin <sup>†</sup>	176 (63.8)	Hypertension, dyslipidaemia	36	<15	1800	118 (-33)	53; nil	124 (-30)	81; nil, terminal illness
M; 49*	2	45; MF	133 (44.8)	Nil	91	<15	1520	87 (34)	29; nil	104 (-22)	33; nil
F; 45	1	47; MF	114 (43.8)	Graves' thyrotoxicosis	32	<15	1800	83 (-27)	40; nil	104 (-9)	52; MF
M; 50	9	78; MF, gliclazide	151 (45.2)	Hypertension, dyslipidaemia, gout	77	<15	2330	81 (-47)	33; nil	80 (-47)	36; nil
M; 51	12	51; MF, insulin <sup>†</sup>	101 (35.3)	Dyslipidaemia	66	<15	687	77 (-24)	43; nil	85 (-16)	41; nil
F; 50	10	74; MF, exenatide, pioglitazone	118 (39.9)	Dyslipidaemia	31	109	822	76 (-35)	50; nil	61 (-48)	42; nil
M; 55*	16	58; MF, pioglitazone	126 (43.5)	Hypertension, dyslipidaemia	16	<15	1010	99 (-21)	50; nil	100 (-21)	54; on MF
F; 48*	10	56; MF	102 (42.1)	Nil	16	<15	1270	87 (-15)	40; nil	100 (0)	47; nil

\*LSG, all others were RYGB; M: male; F: female

<sup>†</sup>Insulin commenced at 5 years after diagnosis; <sup>‡</sup>Insulin commenced at 2.8 years after diagnosis; MF: metformin

<sup>#</sup>Antibodies not repeated post-surgery as patient deceased